Weight loss drug semaglutide studied for energy burn effects
NCT ID NCT06390501
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at how weekly injections of semaglutide (a GLP-1 drug) affect energy expenditure in 60 adults with obesity. Participants received either the drug or a placebo, plus a calorie-restricted diet. Researchers measured changes in total daily energy use, resting metabolism, and physical activity over 24 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY; DRUG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Institute of Advanced Technology
Shenzhen, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.